Detalhe da pesquisa
1.
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
PLoS Med;
21(3): e1004360, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38502656
2.
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.
N Engl J Med;
384(12): 1089-1100, 2021 03 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33761206
3.
Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120.
J Infect Dis;
2023 Oct 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37795976
4.
Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.
PLoS Pathog;
17(3): e1009363, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33720973
5.
Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa.
AIDS Behav;
27(9): 3027-3037, 2023 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36929319
6.
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.
J Infect Dis;
226(2): 246-257, 2022 08 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35758878
7.
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
PLoS Med;
17(5): e1003117, 2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32442195
8.
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
PLoS Med;
17(2): e1003038, 2020 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32092060
9.
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
PLoS Med;
14(11): e1002435, 2017 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29136037
10.
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.
Ann Intern Med;
164(5): 313-22, 2016 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26833336
11.
Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.
Vaccine;
2024 May 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38772835
12.
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial.
EBioMedicine;
100: 104987, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38306894
13.
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
Lancet HIV;
11(5): e285-e299, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38692824
14.
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy Individuals.
medRxiv;
2024 Mar 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38562833
15.
Sexually transmitted infections amongst men who have sex with men (MSM) in South Africa.
PLOS Glob Public Health;
3(4): e0001782, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37018240
16.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine.
medRxiv;
2023 Jan 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36523415
17.
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021.
Open Forum Infect Dis;
10(11): ofad511, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38023544
18.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
Lancet Respir Med;
11(11): 975-990, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37716365
19.
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study.
EClinicalMedicine;
64: 102168, 2023 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37936652
20.
A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers.
Antimicrob Agents Chemother;
56(11): 5946-51, 2012 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22964250